Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Welsh, Robert C. (35239007400)"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial
    (2019)
    Windecker, Stephan (7003473419)
    ;
    Lopes, Renato D. (57203183974)
    ;
    Massaro, Tyler (57220358144)
    ;
    Jones-Burton, Charlotte (9337741100)
    ;
    Granger, Christopher B. (7202019383)
    ;
    Aronson, Ronald (59425124700)
    ;
    Heizer, Gretchen (42561352300)
    ;
    Goodman, Shaun G. (7402115222)
    ;
    Darius, Harald (35416880900)
    ;
    Jones, W. Schuyler (57212876373)
    ;
    Aschermann, Michael (7005976448)
    ;
    Brieger, David (7004107910)
    ;
    Cura, Fernando (6603543967)
    ;
    Engstrøm, Thomas (7004069840)
    ;
    Fridrich, Viliam (6602656890)
    ;
    Halvorsen, Sigrun (9039942100)
    ;
    Huber, Kurt (35376715600)
    ;
    Kang, Hyun-Jae (27171630200)
    ;
    Leiva-Pons, Jose L. (13604803900)
    ;
    Lewis, Basil S. (7401867678)
    ;
    Malaga, German (56481406300)
    ;
    Meneveau, Nicolas (55820664600)
    ;
    Merkely, Bela (7004434435)
    ;
    Milicic, Davor (56503365500)
    ;
    Morais, Joaõ (57210400438)
    ;
    Potpara, Tatjana S. (57216792589)
    ;
    Raev, Dimitar (57192352050)
    ;
    Sabaté, Manel (57193753144)
    ;
    De Waha-Thiele, Suzanne (36189558700)
    ;
    Welsh, Robert C. (35239007400)
    ;
    Xavier, Denis (55403963100)
    ;
    Mehran, Roxana (7004992409)
    ;
    Alexander, John H. (57218960656)
    Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: Patients with ACS treated medically, patients with ACS treated with PCI, and those undergoing elective PCI. Results: Of 4614 patients enrolled, 1097 (23.9%) had ACS treated medically, 1714 (37.3%) had ACS treated with PCI, and 1784 (38.8%) had elective PCI. Apixaban compared with vitamin K antagonist reduced International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding in patients with ACS treated medically (hazard ratio [HR], 0.44 [95% CI, 0.28-0.68]), patients with ACS treated with PCI (HR, 0.68 [95% CI, 0.52-0.89]), and patients undergoing elective PCI (HR, 0.82 [95% CI, 0.64-1.04]; Pinteraction=0.052) and reduced death or hospitalization in the ACS treated medically (HR, 0.71 [95% CI, 0.54-0.92]), ACS treated with PCI (HR, 0.88 [95% CI, 0.74-1.06]), and elective PCI (HR, 0.87 [95% CI, 0.72-1.04]; Pinteraction=0.345) groups. Compared with vitamin K antagonists, apixaban resulted in a similar effect on death and ischemic events in the ACS treated medically, ACS treated with PCI, and elective PCI groups (Pinteraction=0.356). Aspirin had a higher rate of bleeding than did placebo in patients with ACS treated medically (HR, 1.49 [95% CI, 0.98-2.26]), those with ACS treated with PCI (HR, 2.02 [95% CI, 1.53-2.67]), and those undergoing elective PCI (HR, 1.91 [95% CI, 1.48-2.47]; Pinteraction=0.479). For the same comparison, there was no difference in outcomes among the 3 groups for the composite of death or hospitalization (Pinteraction=0.787) and death and ischemic events (Pinteraction=0.710). Conclusions: An antithrombotic regimen consisting of apixaban and a P2Y12 inhibitor without aspirin provides superior safety and similar efficacy in patients with atrial fibrillation who have ACS, whether managed medically or with PCI, and those undergoing elective PCI compared with regimens that include vitamin K antagonists, aspirin, or both. © 2019 American Heart Association, Inc.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Bare metal versus drug eluting stents for ST-segment elevation myocardial infarction in the TOTAL trial
    (2017)
    Lavi, Shahar (57203238237)
    ;
    Iqbal, Javaid (57209172429)
    ;
    Cairns, John A. (7201705929)
    ;
    Cantor, Warren J. (7003446524)
    ;
    Cheema, Asim N. (7004832583)
    ;
    Moreno, Raul (6506647911)
    ;
    Meeks, Brandi (23107081600)
    ;
    Welsh, Robert C. (35239007400)
    ;
    Kedev, Sasko (23970691700)
    ;
    Chowdhary, Saqib (56074610200)
    ;
    Stankovic, Goran (59150945500)
    ;
    Schwalm, J.D. (8099849600)
    ;
    Liu, Yan (57195519602)
    ;
    Jolly, Sanjit S. (55584797122)
    ;
    Džavík, Vladimír (7004450973)
    Background The safety and efficacy of drug eluting stents (DES) in the setting of ST elevation myocardial infarction (STEMI) is not well established. Methods In the TOTAL trial, patients presenting with STEMI were randomized to routine thrombectomy versus PCI alone. In this post-hoc analysis, propensity matching was used to assess relative safety and efficacy according to type of stent used. Results Each propensity-matched cohort included 2313 patients. The composite primary outcome of cardiovascular death, recurrent MI, cardiogenic shock or class IV heart failure within one year was lower in the DES group (HR 0.67; 95% CI 0.54 to 0.84, p = 0.0004). Cardiovascular death (HR 0.61; 95% CI 0.43 to 0.86, p = 0.005), recurrent MI (HR 0.51; 95% CI 0.35 to 0.75, p = 0.0005), target vessel revascularization (HR 0.47; 95% CI 0.36 to 0.62, p < 0.0001) and stent thrombosis (HR 0.60; 95% CI 0.40 to 0.89, p = 0.01) were lower in the DES group. There was no difference in major bleeding between groups. Conclusions In this observational analysis, the use of DES was associated with improvement in cardiovascular outcomes compared to the use of BMS. These results support the use of DES during primary PCI for STEMI. © 2017 Elsevier Ireland Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)
    (2024)
    Bainey, Kevin R. (8064642600)
    ;
    Wood, David A. (57208240062)
    ;
    Bossard, Matthias (55670024300)
    ;
    Campo, Gianluca (8937083300)
    ;
    Cantor, Warren J. (7003446524)
    ;
    Lavi, Shahar (57203238237)
    ;
    Madan, Mina (7102357147)
    ;
    Mehran, Roxana (7004992409)
    ;
    Pinilla-Echeverri, Natalia (55315146100)
    ;
    Rao, Sunil (57216409009)
    ;
    Sarma, Jaydeep (35724660400)
    ;
    Sheth, Tej (6602892196)
    ;
    Stankovic, Goran (59150945500)
    ;
    Steg, Phillipe Gabriel (57203081180)
    ;
    Storey, Robert F. (7101733693)
    ;
    Tanguay, Jean-Francois (7003916903)
    ;
    Velianou, James L. (6602617374)
    ;
    Welsh, Robert C. (35239007400)
    ;
    Mani, Thenmozhi (56825619800)
    ;
    Cairns, John A. (7201705929)
    ;
    Mehta, Shamir R. (57212016579)
    Background: In ST-segment elevation myocardial infarction (STEMI), complete revascularization with percutaneous coronary intervention (PCI) reduces major cardiovascular events compared with culprit-lesion-only PCI. Whether age influences these results remains unknown. Methods: COMPLETE was a multinational, randomized trial evaluating a strategy of staged complete revascularization, consisting of angiography-guided PCI of all suitable nonculprit lesions, versus a strategy of culprit-lesion-only PCI. In this prespecified subgroup analysis, treatment effect according to age (≥65 years vs <65 years) was determined for the first coprimary outcome of cardiovascular (CV) death or new myocardial infarction (MI) and the second coprimary outcome of CV death, new MI, or ischemia-driven revascularization (IDR). Median follow-up was 35.8 months (interquartile range [IQR]: 27.6-44.3 months). Results: Of 4,041 patients randomized in COMPLETE, 1,613 were aged ≥ 65 years (39.9%). Higher event rates were observed for both coprimary outcomes in patients aged ≥ 65 years comparted with those aged < 65 years (11.2% vs 7.9%, HR 1.49, 95% CI 1.22-1.83; 14.4% vs 11.8%, HR 1.28, 95% CI 1.07-1.52, respectively). Complete revascularization reduced the first coprimary outcome in patients ≥ 65 years (9.7% vs 12.5%, HR 0.77; 95% CI, 0.58-1.04) and < 65 years (6.7% vs 9.1%, HR 0.72; 95% CI, 0.54-0.96)(interaction P = .74). The second coprimary outcome was reduced in those ≥ 65 years (HR 0.56, 95% CI, 0.43-0.74) and < 65 years (HR 0.48, 95% CI, 0.37-0.61 (interaction P = .37). A sensitivity analysis was performed with consistent results demonstrated using a 75-year threshold (albeit attenuated). Conclusions: In patients with STEMI and multivessel CAD, complete revascularization compared with culprit-lesion-only PCI reduced major cardiovascular events regardless of patient age and could be considered as a revascularization strategy in older adults. © 2023 Elsevier Inc.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction
    (2013)
    Armstrong, Paul W. (35380325200)
    ;
    Gershlick, Anthony H. (7005330722)
    ;
    Goldstein, Patrick (7103144663)
    ;
    Wilcox, Robert (36658310600)
    ;
    Danays, Thierry (6602776421)
    ;
    Lambert, Yves (7004159091)
    ;
    Sulimov, Vitaly (7006306238)
    ;
    Ortiz, Fernando Rosell (24067315600)
    ;
    Ostojic, Miodrag (34572650500)
    ;
    Welsh, Robert C. (35239007400)
    ;
    Carvalho, Antonio C. (55426495300)
    ;
    Nanas, John (7006860321)
    ;
    Hans-Richard Arntz, Sigrun Halvorsen (55644411000)
    ;
    Huber, Kurt (35376715600)
    ;
    Grajek, Stefan (7006095413)
    ;
    Fresco, Claudio (7003822117)
    ;
    Bluhmki, Erich (8049126600)
    ;
    Regelin, Anne (55645504400)
    ;
    Vandenberghe, Katleen (16742916200)
    ;
    Bogaerts, Kris (6701596663)
    ;
    Van De Werf, Frans (36048879600)
    BACKGROUND: It is not known whether prehospital fibrinolysis, coupled with timely coronary angiography, provides a clinical outcome similar to that with primary percutaneous coronary intervention (PCI) early after acute ST-segment elevation myocardial infarction (STEMI). METHODS: Among 1892 patients with STEMI who presented within 3 hours after symptom onset and who were unable to undergo primary PCI within 1 hour, patients were randomly assigned to undergo either primary PCI or fibrinolytic therapy with bolus tenecteplase (amended to half dose in patients ≥75 years of age), clopi;dogrel, and enoxaparin before transport to a PCI-capable hospital. Emergency coronary angiography was performed if fibrinolysis failed; otherwise, angiography was performed 6 to 24 hours after randomization. The primary end point was a composite of death, shock, congestive heart failure, or reinfarction up to 30 days. Results The primary end point occurred in 116 of 939 patients (12.4%) in the fibrinolysis group and in 135 of 943 patients (14.3%) in the primary PCI group (relative risk in the fibrinolysis group, 0.86; 95% confidence interval, 0.68 to 1.09; P = 0.21). Emergency angiography was required in 36.3% of patients in the fibrinolysis group, whereas the remainder of patients underwent angiography at a median of 17 hours after randomization. More intracranial hemorrhages occurred in the fibrinolysis group than in the primary PCI group (1.0% vs. 0.2%, P = 0.04; after protocol amendment, 0.5% vs. 0.3%, P = 0.45). The rates of nonintracranial bleeding were similar in the two groups. CONCLUSIONS: Prehospital fibrinolysis with timely coronary angiography resulted in effective reperfusion in patients with early STEMI who could not undergo primary PCI within 1 hour after the first medical contact. However, fibrinolysis was associated with a slightly increased risk of intracranial bleeding. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00623623.) Copyright © 2013 Massachusetts Medical Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Randomized trial of primary PCI with or without routine manual thrombectomy
    (2015)
    Jolly, Sanjit S. (55584797122)
    ;
    Cairns, John A. (7201705929)
    ;
    Yusuf, Salim (7202749318)
    ;
    Meeks, Brandi (23107081600)
    ;
    Pogue, Janice (35371599700)
    ;
    Rokoss, Michael J. (8895026900)
    ;
    Kedev, Sasko (23970691700)
    ;
    Thabane, Lehana (6603556364)
    ;
    Stankovic, Goran (59150945500)
    ;
    Moreno, Raul (6506647911)
    ;
    Gershlick, Anthony (7005330722)
    ;
    Chowdhary, Saqib (56074610200)
    ;
    Lavi, Shahar (57203238237)
    ;
    Niemelä, Kari (7003504049)
    ;
    Steg, Philippe Gabriel (56212505300)
    ;
    Bernat, Ivo (23967691900)
    ;
    Xu, Yawei (59880712600)
    ;
    Cantor, Warren J. (7003446524)
    ;
    Overgaard, Christopher B. (9533641300)
    ;
    Naber, Christoph K. (35550938600)
    ;
    Cheema, Asim N. (7004832583)
    ;
    Welsh, Robert C. (35239007400)
    ;
    Bertrand, Olivier F. (7006736607)
    ;
    Avezum, Alvaro (7003859797)
    ;
    Bhindi, Ravinay (57203195611)
    ;
    Pancholy, Samir (55883087600)
    ;
    Rao, Sunil V. (7404177964)
    ;
    Natarajan, Madhu K. (7102581788)
    ;
    Ten Berg, Jurriën M. (7003930354)
    ;
    Shestakovska, Olga (54929885000)
    ;
    Gao, Peggy (35069449800)
    ;
    Widimsky, Petr (56362669800)
    ;
    Džavík, Vladimír (7004450973)
    Background: During primary percutaneous coronary intervention (PCI), manual thrombectomy may reduce distal embolization and thus improve microvascular perfusion. Small trials have suggested that thrombectomy improves surrogate and clinical outcomes, but a larger trial has reported conflicting results. Methods: We randomly assigned 10,732 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI to a strategy of routine upfront manual thrombectomy versus PCI alone. The primary outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, cardiogenic shock, or New York Heart Association (NYHA) class IV heart failure within 180 days. The key safety outcome was stroke within 30 days. Results: The primary outcome occurred in 347 of 5033 patients (6.9%) in the thrombectomy group versus 351 of 5030 patients (7.0%) in the PCI-alone group (hazard ratio in the thrombectomy group, 0.99; 95% confidence interval [CI], 0.85 to 1.15; P = 0.86). The rates of cardiovascular death (3.1% with thrombectomy vs. 3.5% with PCI alone; hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.34) and the primary outcome plus stent thrombosis or target-vessel revascularization (9.9% vs. 9.8%; hazard ratio, 1.00; 95% CI, 0.89 to 1.14; P = 0.95) were also similar. Stroke within 30 days occurred in 33 patients (0.7%) in the thrombectomy group versus 16 patients (0.3%) in the PCI-alone group (hazard ratio, 2.06; 95% CI, 1.13 to 3.75; P = 0.02). Conclusions: In patients with STEMI who were undergoing primary PCI, routine manual thrombectomy, as compared with PCI alone, did not reduce the risk of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days but was associated with an increased rate of stroke within 30 days. Copyright © 2015 Massachusetts Medical Society.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback